Shlomo Melmed
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1700815180
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $133,042 of the $176,817 with a category attached, or 75.2%. Novo Nordisk Health Care AG accounts for 65.7% of it on its own, with 10 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $3157.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk Health Care AG$116K
- Chiasma, Inc.$17K
- Novo Nordisk$15K
- Recordati_rare_diseases_inc.$8K
- AstraZeneca$6K
- Ipsen Biopharmaceuticals, Inc$4K
- plus $11K from 5 others
Across 39 payments — averaging $80,146 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$3.1M
What the payments were for
- Consulting fees$133,04275%
- Speaking & faculty fees$13,0907%
- Travel & lodging$29,02316%
- Food & beverage$1,6621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk Health Care AG | 28 | $116,225 |
| Chiasma, Inc. | 2 | $17,442 |
| Novo Nordisk | 5 | $14,500 |
| Recordati_rare_diseases_inc. | 6 | $7,842 |
| AstraZeneca | 4 | $5,975 |
| Ipsen Biopharmaceuticals, Inc | 2 | $3,870 |
| Ipsen Innovation | 2 | $3,678 |
| Ipsen Pharma SAS | 1 | $2,580 |
| Pfizer | 2 | $2,477 |
| Ipsen Biopharm Limited | 1 | $2,100 |
| Amryt Pharma Holdings Ltd | 3 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$17,550
- SOMATULINE DEPOT$12,228
- Norditropin$5,940
- ISTURISA$3,300
- SOMAVERT$2,360
- OSILODROSTAT$1,750
How this compares
$176,817 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in Los Angeles
- Anthony HeaneyLos Angeles$588K
- Christian GastelumLos Angeles$321K
- Sina TebiLos Angeles$133K
- Glenn BraunsteinLos Angeles$113K
- Laurence KatznelsonLos Angeles$99K
- John CarmichaelLos Angeles$90K
- Peter ButlerLos Angeles$58K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.